Nothing on this site is intended for human or veterinary use. PeptideBasics101 exists for general awareness: it collects publicly available information from across the internet and keeps it in one place for research and entertainment purposes only. Nothing here is medical advice. Statements here are our summaries of public sources and have not been reviewed or endorsed by the FDA or any regulatory body. This is information gathering, not guidance.

PeptideBasics101

peptide

Retatrutide

An investigational once-weekly triple agonist of the GIP, GLP-1 and glucagon receptors from Eli Lilly, with Phase 3 obesity results reported in 2025–2026. Not approved anywhere.

Data refreshed 2026-09-24 · Based on 8 published references

Names

Generic: retatrutide

Also called: LY3437943, reta, triple G, GGG

Regulatory (US)

FDA approval: investigational

503A compounding: restricted

Molecule

Formula: C221H342N46O68

MW: 4731 g/mol

CAS: 2381089-83-2

PubChem entry

Origin

Discovered by: Tamer Coskun and colleagues, Eli Lilly

Year: 2022

Developer: Eli Lilly and Company

What it is

Retatrutide is an experimental Lilly peptide that imitates three hormones at once: GIP, GLP-1 and glucagon. The first two are the same targets as tirzepatide. Adding glucagon is meant to raise energy expenditure and clear fat from the liver. In Lilly’s main Phase 3 obesity trial, the highest dose produced an average weight loss of about 28% over 80 weeks, according to the company.

It is not approved anywhere. It exists only inside clinical trials. Anything sold under this name outside a trial is not the product being tested.

Retatrutide (LY3437943) is a single-chain synthetic peptide derived from a GIP scaffold and lipidated with a C20 fatty diacid for albumin binding. In vitro it shows more activity at the GIP receptor than at the GLP-1 and glucagon receptors, where its activity is roughly balanced (Coskun et al., 2022). Glucagon receptor agonism is intended to increase hepatic fatty acid oxidation and energy expenditure, while GLP-1 and GIP agonism suppress appetite and blunt glucagon-driven hyperglycaemia. In obese mice, glucagon-receptor-driven increases in energy expenditure added to the intake reduction from GIP and GLP-1 agonism. Its half-life in Phase 1 was about 6 days, supporting once-weekly dosing.

Who made it and when

Lilly’s peptide group, again including Tamer Coskun, published the molecule in 2022. Phase 2 results came out in 2023 and the Phase 3 program, called TRIUMPH, started the same year. The first Phase 3 readout came in December 2025, the main obesity trial in May 2026, and the diabetes and heart-disease trials in July 2026. Lilly has said it plans to file for US approval in the first quarter of 2027.

Coskun and colleagues described the design and preclinical pharmacology in Cell Metabolism in 2022. Phase 2 obesity (n=338) and type 2 diabetes (n=281) trials read out in 2023. The TRIUMPH program comprises TRIUMPH-1 (obesity, with knee osteoarthritis and sleep apnoea sub-studies), TRIUMPH-2 (obesity with T2D), TRIUMPH-3 (severe obesity with established CVD), TRIUMPH-4 (obesity with knee osteoarthritis) and additional outcome and comparator studies. Topline dates: TRIUMPH-4 2025-12-11, TRIUMPH-1 2026-05-21, TRIUMPH-2 and -3 2026-07-23. Lilly stated in July 2026 that it plans to submit to the FDA in Q1 2027. Patent filings are held by Eli Lilly.

What the data say

In the mid-stage obesity trial, people on the highest dose lost about 24% of body weight in 48 weeks and were still losing at the end. A liver sub-study showed most participants’ liver fat fell into the normal range. In Phase 3, Lilly reports average losses of about 28% at 80 weeks in people without diabetes, about 21% in people with type 2 diabetes, and about 23% in people with heart disease. None of the Phase 3 results has yet appeared in a peer-reviewed journal. The main side effects were stomach upset during dose increases, a faster heart rate and unusual skin sensations.

Phase 2 (NCT04881760): 12 mg produced −24.2% body weight at 48 weeks vs −2.1% placebo; 100% of the 8 and 12 mg groups reached 5% or greater loss. The MASLD sub-study (n=98) reported relative liver-fat reductions of −81.4% (8 mg) and −82.4% (12 mg) at 24 weeks, with normal liver fat (under 5%) in 79% and 86%. Dose-dependent heart-rate increases peaked at 24 weeks and declined thereafter. Phase 3 toplines (company disclosures, efficacy estimand): TRIUMPH-1 −28.3% at 12 mg vs −2.2% placebo at 80 weeks, and −30.3% at 104 weeks in the BMI 35 or higher extension; TRIUMPH-2 −20.8% vs −4.0% with HbA1c down 1.5–1.6 points at 9–12 mg; TRIUMPH-3 −22.6% vs −3.2%; TRIUMPH-4 −28.7% at 68 weeks. These figures remain provisional until peer-reviewed publication.

Regulatory picture

Retatrutide has no approval anywhere and Lilly had not filed for one as of its July 2026 update. The FDA states that retatrutide cannot legally be used in compounding and is not part of any FDA-approved drug. The agency has sent warning letters to telehealth companies, ingredient distributors and sellers of “research use” products involving retatrutide. Products sold online as “retatrutide” are unapproved drugs of unknown identity.

Retatrutide is an investigational new drug under IND. It is not a component of any approved product and has no USP monograph. FDA’s guidance page on unapproved GLP-1 drugs states that retatrutide cannot be used in compounding under federal law, so neither the 503A nor the 503B pathway is available. FDA reports warning letters to telehealth companies for marketing retatrutide directly to consumers, to active pharmaceutical ingredient distributors for selling it to compounders, to outsourcing facilities for repackaging it, and to firms selling it labelled “for research purposes”. Lilly has said it plans a US marketing submission in the first quarter of 2027 based on the TRIUMPH program.

Doses reported in trials

Doses reported in studies, exactly as the cited trial reported them. They are not personal dosing instructions. Population, route and schedule matter more than the number.

TrialPhaseStatusPopulationDoseResult
Phase 2 obesity study
NCT04881760
2Completed338 adults with obesity or overweight plus comorbidity, no diabetes1, 4, 8 or 12 mg subcutaneous once weekly, with starting doses of 2 or 4 mg and escalation, 48 weeks−24.2% body weight at 12 mg vs −2.1% placebo at 48 weeks (Jastreboff et al., NEJM 2023)
Phase 2 type 2 diabetes study
NCT04867785
2Completed281 adults with type 2 diabetes0.5 to 12 mg subcutaneous once weekly vs placebo and dulaglutide 1.5 mg, 36 weeksHbA1c −2.02 points at 12 mg vs −0.01 placebo at 24 weeks; body weight −16.9% at 12 mg at 36 weeks (Rosenstock et al., Lancet 2023)
TRIUMPH-1
NCT05929066
3Completed2,339 adults with obesity, or overweight plus a weight-related condition, without diabetes; includes knee osteoarthritis and sleep apnoea sub-studies4, 9 or 12 mg subcutaneous once weekly vs placebo, 80 weeks; extension to 104 weeks in participants with BMI 35 or higherCompany-reported May 2026: −19.0%, −25.9% and −28.3% body weight at 4, 9 and 12 mg vs −2.2% placebo at 80 weeks (efficacy estimand); −17.6% to −25.0% vs −3.9% by treatment-regimen estimand. Peer-reviewed publication pending.
TRIUMPH-2
NCT05929079
3Completed1,152 adults with type 2 diabetes and obesity or overweight (BMI 27 or higher)4, 9 or 12 mg subcutaneous once weekly vs placebo, 80 weeksCompany-reported July 2026: −12.7%, −19.1% and −20.8% body weight vs −4.0% placebo at 80 weeks (efficacy estimand); HbA1c reduced by up to 1.6 points vs 0.2 with placebo. Peer-reviewed publication pending.
TRIUMPH-3
NCT05882045
3Completed1,949 adults with BMI 35 or higher and established cardiovascular disease, with or without type 2 diabetes9 or 12 mg subcutaneous once weekly vs placebo, 80 weeksCompany-reported July 2026: −21.6% and −22.6% body weight vs −3.2% placebo at 80 weeks (efficacy estimand). The primary endpoint was body weight; cardiovascular events were few (3-point MACE hazard ratio 1.12, 95% CI 0.64–1.96). Peer-reviewed publication pending.
TRIUMPH-4
NCT05931367
3Completed445 adults with obesity or overweight and knee osteoarthritis9 or 12 mg subcutaneous once weekly vs placebo, 68 weeksCompany-reported December 2025: up to −28.7% body weight at 12 mg and WOMAC pain reduced by up to 4.5 points (75.8%) at 68 weeks. Peer-reviewed publication pending.

Enforcement history

Reported side effects

Interactions

Contraindications

Storage

No approved product exists, so there is no label storage guidance. Research-grade lyophilized powder is typically shipped and stored frozen; supplier claims for reconstituted stability are not label data.

Product characteristics

Form: Investigational solution for subcutaneous injection; research grade sold as lyophilized powder

Stability: Lipidated for albumin binding; half-life supports once-weekly dosing (about 6 days in Phase 1)

Compound information

Synthetic single-chain peptide engineered from a GIP-based scaffold with a C20 fatty diacid for albumin binding. PubChem lists the formula as C221H342N46O68 (CID 171390338).

References

This page summarises the published sources below. PeptideBasics101 does no original research. Trial doses and results are reported as the cited study or label reported them. Sources can themselves be wrong or superseded; if you find a statement here that does not match its source, please tell us through our corrections process. Sources were last checked on 2026-09-24.

  1. Jastreboff AM et al. Triple-hormone-receptor agonist retatrutide for obesity: a phase 2 trial. NEJM 2023 (nejm.org)
  2. Rosenstock J et al. Retatrutide in type 2 diabetes: a randomised phase 2 trial. Lancet 2023 (doi.org)
  3. Coskun T et al. LY3437943, a novel triple glucagon, GIP and GLP-1 receptor agonist. Cell Metab 2022 (doi.org)
  4. Sanyal AJ et al. Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease. Nat Med 2024 (doi.org)
  5. Eli Lilly: TRIUMPH-1 topline results (press release, 2026-05-21) (prnewswire.com)
  6. Eli Lilly: TRIUMPH-2 and TRIUMPH-3 topline results (press release, 2026-07-23) (prnewswire.com)
  7. FDA: concerns with unapproved GLP-1 drugs used for weight loss (fda.gov)
  8. PubChem: retatrutide (pubchem.ncbi.nlm.nih.gov)

Clinical trial entries in the table above link to their ClinicalTrials.gov registry records. Spotted an error? See corrections.

Ask Sgt. Pep